GlobeNewswire Inc | Jun 21, 2021 08:00AM EDT

June 21, 2021

EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced thatmembers of its management team will participate in two upcoming investor conferences: the Raymond James Human Health Innovation Conference and SVB Leerink CNS Forum.

Raymond James Human Health Innovation ConferencePanel: Recent Advancements & Future Directions in the Treatment of EpilepsyDate: Wednesday, June 23, 2021Time: 4:00 PM Eastern TimePresenter: Michael Smith, Executive Vice President and Chief Financial Officer SVB Leerink CNS ForumFireside Reviewing Two Underappreciated Zogenix AssetsChat:Date: Tuesday, June 29, 2021Time: 11:50 AM Eastern Time Stephen J. Farr, Ph.D., President and Chief Executive OfficerPresenters: andMichael Smith, Executive Vice President and Chief Financial Officer

About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs, one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

CONTACTS:

ZogenixMelinda BakerSenior Director, Corporate Communications+1 (510) 788-8732 |corpcomms@zogenix.com

InvestorsBrian RitchieManaging Director,LifeSci Advisors LLC+1 (212) 915-2578 |britchie@lifesciadvisors.com

MediaStefanie Tuck, Vice President, Porter Novelli+1 (978) 390-1394 | stefanie.tuck@porternovelli.com